Sibrafiban
Jump to navigation
Jump to search
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H28N4O6 |
Molar mass | 420.466 g·mol−1 |
3D model (JSmol) | |
| |
|
Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI).[1] On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.
See also
References
Categories:
- Articles with short description
- Short description matches Wikidata
- Chemical pages without DrugBank identifier
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Abandoned drugs
- Amidines
- Benzamides
- Glycoprotein IIb/IIIa inhibitors
- Oximes
- Piperidines
- Prodrugs
- All stub articles
- Blood and blood forming organ drug stubs